Lymphoma Hub on X: "CONGRESS | #ASH20 | Arnon Kater, @amsterdamumc, reports long term results in phase III MURANO study of fixed-duration venetoclax-rituximab with standard bendamustine-rituximab in R/R CLL. 5-yr data showed
Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) - ScienceDirect
MURANO: Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed/refractory
MURANO Trial: Venetoclax Plus Rituximab Achieves Durable Progression-Free Survival in Resistant CLL - The ASCO Post
Journal of Clinical Oncology on X: "Four-year follow up of relapsed/refractory CLL in MURANO trial shows improved survival with venetoclax-rituximab compared to bendamustine-rituximab https://t.co/O6agxSZDcX #leusm #lymsm @PeterMacCC https://t.co ...
Relapsed / Refractory CLL | Haematology | AbbVie UK
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab - ScienceDirect
VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL
Vaso CARLO MORETTI Collezione "I piccoli" Vetro di MURANO Made in Italy Edizione Limitata ORION : Amazon.it: Casa e cucina
Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study
VENCLEXTA® (venetoclax tablets) | VEN+R Safety Data for CLL/SLL
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study | Haematologica
Updated results from the phase III MURANO trial - BJH
4-year results from the phase III MURANO study
Jeff Szer on X: "John Seymour from Melbourne presenting MURANO outcomes: randomised venetoclax and rituximab in CLL at late Breaking abstracts #ASH17. The venetoclax juggernaut continues to be positive. https://t.co/LeKlANNjzq" / X
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study | Haematologica
Lymphoma Hub on X: "#EHA2023 | Arnon Kater @amsterdamumc shares the final 7-year follow up data from the MURANO trial of VenR in R/RCLL. OS 69.6% and 51% in VenR and BR
Jeff Szer on X: "John Seymour from @Haem_pmcc_rmh presenting MURANO trial of time-limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). #ASH18 https://t.co/aCOdDI4yC2" / X
Relapsed / Refractory CLL | Haematology | AbbVie UK
5-year data show sustained benefit of venetoclax-rituximab for relapsed/refractory CLL
CLL: The main clinical message from the Five-Year Analysis of Murano Study
MURANO study supports the use of fixed-duration VenR in R/R CLL
VenR for R/R CLL: 5-Yr FU - Slideset Download - Hematology 2020 | CCO
Vaso CARLO MORETTI Collezione "I piccoli" Vetro di MURANO Made in Italy Edizione Limitata ORION : Amazon.it: Casa e cucina
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - LIPA
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: <i>post-hoc</i> analyses from the phase III MURANO study | Haematologica
Mednet - CME, CHE | A New Era of Chemotherapy-free Treatments Emerges for Chronic Lymphocytic Leukemia
John F. Seymour, MBBS, PhD, on CLL: Results From the MURANO Study
Relapsed / Refractory CLL | Haematology | AbbVie UK
